Malignant Mesothelioma Patient Population to Increase to 2023, States DelveInsight in Its Report Available at MarketPublishers.com17 Feb 2017 • by Natalie Aster
LONDON – Malignant mesothelioma (mesothelioma) is a lethal and rare tumour that have an adverse influence on the thin lining (membrane) – the mesothelium. This asbestos-related cancer develops in the thin protective tissues that surround the abdomen, lungs, and, in rare conditions, the heart and testicles. The survival time since diagnosis is approximately 9-12 months.
The number of mesothelioma patients is forecast to gain traction through to 2023, leading to a dramatic hike in the global market value by that time.
The most typical of the 4 categories of malignant mesothelioma is malignant pleural mesothelioma, which badly impacts the lining of lungs and comes from breathing of asbestos fibers. This mesothelioma type captures about 70% of total cases diagnosed every year in 7MM. Around 2,500 humans are diagnosed with pleural mesothelioma annually.
With the absence of any cure for mesothelioma and poor outlook, medical researchers have made great strides in gaining a deeper understanding of the cancer and creating novel treatment modalities and alternative therapies. To date, standard treatments of all mesothelioma types include surgery, and radiation, and chemotherapy.
Topical research report “Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast – 2023 - 7MM” created by DelveInsight provides all-round, detailed insights into the mesothelioma marketplace across the 7MM. The study presents a comprehensive, unbiased overview of the disease including pathologic physiology, symptoms, diagnosis, disease management, and today’s treatment modes. It includes detailed marketed data covering existing prescription medicines, as well as patent and exclusivity issues. Furthermore, the report provides market size of the malignant mesothelioma marketplace across 7MM for 2010-2023; includes epidemiological figures, historical and forecast, for the diagnosed prevalent cases of mesothelioma.
More topical research publications by the publisher are available at DelveInsight page.